

BMJ Open Serum lactate cut-offs as a risk stratification tool for in-hospital adverse outcomes in emergency department patients screened for suspected sepsis

Amith L Shetty,^{1,2} Kelly Thompson,³ Karen Byth,^{4,5} Petra Macaskill,⁶ Malcolm Green,⁷ Mary Fullick,⁷ Harvey Lander,⁸ Jonathan Iredell^{1,9}

To cite: Shetty AL, Thompson K, Byth K, *et al.* Serum lactate cut-offs as a risk stratification tool for in-hospital adverse outcomes in emergency department patients screened for suspected sepsis. *BMJ Open* 2018;**8**:e015492. doi:10.1136/bmjopen-2016-015492

► Prepublication history and additional material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2016-015492>).

Received 14 December 2016

Revised 17 November 2017

Accepted 21 November 2017

ABSTRACT

Objectives We investigated specific lactate thresholds for adverse outcomes in patients presenting to emergency departments (EDs) with suspected sepsis identified based on the performance of a sepsis screening algorithm.

Design and setting A standardised sepsis bundle was implemented across public hospitals in New South Wales, Australia, as a quality improvement initiative. A register of all adult ED presentations (≥ 18 years) meeting predefined criteria for sepsis was created, using a combination of data linkage and direct reporting from 97 participating sites.

Participants A total of 12 349 adult ED presentations with 8310 (67.3%) having serum lactate analysis on arrival. Analysis of outcomes was based on dataset for 12 349 subjects obtained through multiple imputation for missing data.

Interventions A sepsis management bundle including early antibiotic prescribing, fluid therapy and referral to intensive care unit (ICU) services was implemented.

Outcome measures A primary composite adverse event (AE) outcome of in-hospital mortality (IHM) and/or prolonged ICU stay ≥ 72 hours (ICU 72 hours) was used for this study.

Results There was statistically significant increase both in the ORs of AE and IHM with each integer increase in serum lactate values. After adjusting for the presence of hypotension, the estimated ORs for the combined AE outcome were 2.71 (95% CI 2.05 to 3.57), 2.65 (95% CI 2.29 to 3.08), 3.10 (95% CI 2.71 to 3.53) and 3.89 (95% CI 3.36 to 4.50) for serum lactate levels at or above 1, 2, 3 and 4 mmol/L, respectively. The corresponding ORs for IHM were 2.93 (95% CI 2.08 to 4.13), 2.77 (95% CI 2.34 to 3.29), 3.26 (95% CI 2.80 to 3.80) and 4.01 (95% CI 3.40 to 4.73), respectively (all $P < 0.0001$). More than 10% of patients with suspected sepsis and with serum lactate ≥ 2 mmol/L experienced a prolonged ICU stay or died in hospital.

Conclusions ED sepsis screening algorithms intended to identify patient adverse outcomes should incorporate a serum lactate cut-off of ≥ 2 mmol/L as a threshold for the initiation of specific interventions and increased monitoring.

INTRODUCTION

Sepsis is the life-threatening condition that results from dysregulated host response

Strengths and limitations of this study

- A retrospective analysis of a large statewide dataset of patients with suspected sepsis based on performance of a specific sepsis screening algorithm across 97 hospital sites in the most populous state in Australia, with outcome data on 12 349 patients.
- Data were reported voluntarily as part of a quality improvement initiative and clinical practices may have varied between sites. The results can therefore be generalised to working emergency departments (EDs) in this state but lack the rigour of a well-controlled research study.
- Glasgow Coma Scale information was not collected and other systemic inflammatory response syndrome (SIRS) data (eg, respiratory rate) were incomplete, preventing full quick Sequential Organ Failure Assessment analysis.
- Lactate levels were available on 67.3% and systolic blood pressure on 92.2% of the cohort. Multiple imputation was used to populate missing data variables to reduce potential bias due to missing data.
- Patients were placed on the sepsis pathway through SIRS-based screening and therefore may not represent the complete cohort of patients with sepsis presenting to the participating EDs.

to infection and organ dysfunction¹ and is responsible for one-third to one-half of all deaths in hospital.² Early recognition and prompt treatment offer the best chance of survival but early diagnosis of sepsis presents a challenge.

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) (box) rejected systemic inflammatory response syndrome (SIRS) diagnostic criteria³ in favour of organ failure assessment criteria. For clinical operationalisation, organ dysfunction has been represented by an increase in the Sequential (Sepsis-related) Organ Failure Assessment (SOFA) score of 2 points



CrossMark

For numbered affiliations see end of article.

Correspondence to

Dr Amith L Shetty;
amith.shetty@sydney.edu.au

Box Sepsis-3 definitions and cut-offs used for the study**SOFA criteria sepsis definition (2016):**

- ▶ Suspected infection.
- ▶ An acute change in SOFA score of ≥ 2 points consequent to infection.

qSOFA*:

- ▶ Low blood pressure (systolic blood pressure ≤ 100 mm Hg).
- ▶ High respiratory rate (≥ 22 breaths per min).
- ▶ Altered mentation (Glasgow Coma Scale < 15).

Notes: *Patients are assigned 1 point for each qSOFA criteria met. The presence of ≥ 2 qSOFA points near the onset of infection is associated with a greater risk of death or prolonged intensive care unit stay.

qSOFA, quick Sequential Organ Failure Assessment; Sepsis-3, Third International Consensus Definitions for Sepsis and Septic Shock; SOFA, Sequential Organ Failure Assessment.

or more.¹ The Sepsis-3 working group used a combined adverse event (AE) (prolonged intensive care unit (ICU) stay ≥ 72 hours or death in hospital) as a marker of adverse outcomes that are typical of sepsis rather than uncomplicated infection. An abbreviated quick SOFA (qSOFA) tool has been developed from the SOFA score¹: 2 or more qSOFA points in patients with suspected infection predict increased risk for this combined adverse outcome (box).

Serum lactate is not part of the SOFA score,⁴ but lactate remains part of the septic shock definition, a key resuscitation target in the Surviving Sepsis Campaign (SCC) guidelines⁵ and in sepsis management bundles worldwide.⁶ A recent Australian study found hyperlactatemia to be a stronger mortality predictor than refractory hypotension⁷ and abnormal lactate levels were previously considered in definitions of severe sepsis.³ An increased risk of death has also been reported in association with elevations in serum lactate in those with suspected sepsis,⁸ and this risk rises exponentially with rise in lactate levels.^{8,9}

There is increasing evidence that sepsis-associated hyperlactatemia is driven at least in part by increased aerobic glycolysis secondary to the stress response rather than simple tissue hypoxaemia or hypoperfusion and is indicative of disease severity.¹⁰ Sepsis screening algorithms aim to identify patients at higher risk of adverse outcomes.¹¹ We hypothesised that raised lactate levels (≥ 2 mmol/L) in the emergency department (ED) would predict higher risk for adverse outcomes (in-hospital mortality (IHM) and/or ICU stay ≥ 72 hours), independent of the presence of hypotension at ≤ 100 mm Hg as recently promulgated by the qSOFA tool.

METHODS

We conducted a retrospective analysis of data from the Clinical Excellence Commission (CEC) SEPSIS KILLS initiative, a statewide quality improvement programme implemented in 180 public hospitals in New South Wales (NSW), Australia, which aims to improve recognition and treatment of sepsis in ED and inpatient units across the state (online supplementary appendix). Data

were prospectively collected from voluntary reporting at participating sites.¹² As part of the SEPSIS KILLS pathway implementation, sites were required to report SIRS variables and investigations (lactate level) at the time of initiation of the sepsis management bundle. However, this was not separately verified and strong inferences regarding the optimal timing of SIRS and lactate investigations cannot be made from these data. Patients were identified at each site based on the sepsis screening tool in the SEPSIS KILLS programme.¹² Management was guided by local protocols with an emphasis on fluid resuscitation and antibiotic administration within 60 minutes. Ethics approval was obtained for the NSW Sepsis Register, developed as a public health and disease register under the Public Health Act 2011.

Site and patient selection

The SEPSIS KILLS programme was implemented in a phased approach across NSW public hospital EDs and at the time of analysis, 97 sites had contributed to the Sepsis Register. We retrieved data for adult patients (aged 18 years and over) presenting to ED who were entered into the Sepsis Register between June 2010 and December 2013. Data were linked to patient outcomes. The process of data collection for the register as well as the health and hospital outcomes data derived through data linkage (which includes ICU length of stay and/or IHM) has been previously described.¹²

Outcome measures

In view of the adverse outcome used by Sepsis-3 to differentiate sepsis from uncomplicated infection, we defined a composite combined AE of IHM and/or ICU 72 hours as the primary outcome for the study.^{1,12} We report on IHM as an important secondary outcome for our study.

Variables available for analysis

Complete de-identified data were available for age, triage category, presumed source of infection, IHM and ICU 72 hours, but not all patients had lactate measurements or systolic blood pressure (SBP) values. Glasgow Coma Scale values were not recorded on the database. Hospital location and practice model information was available at an overall descriptive level but were not linked to outcomes.

Statistical analysis

Fully conditional multiple imputation was used to replace missing lactate and SBP measurements using the imputation sequence age, triage category, presumed source, IHM status, ICU 72 hours status, SBP and lactate. Thirty datasets were imputed and pooled imputed estimates were derived for summary statistics and for ORs from the logistic regression models. All covariates and outcomes were included in the imputation model ($n=30$) as per statistical principles.^{13,14} To address the specific aim of the study to investigate initial serum lactate thresholds, lactate levels were categorised into ranges (<1 , 1 to <2 , 2 to <3 , 3 to <4 , ≥ 4 mmol/L) and the proportion who

suffered either IHM or ICU 72 hours (either or both AE) and the proportion who died in hospital (IHM) were calculated in each lactate category. The multiple imputation and subsequent analyses were performed using IBM SPSS Statistics V.23.0.¹⁵

Distributions for age, lactate and SBP were summarised using the median value and IQR. Percentages were used to summarise categorical variables. Exact 95% CIs were computed for percentages.

For both AE and IHM, a test for trend in proportions across lactate categories was conducted. For each category, logistic regression was used to estimate the OR and corresponding 95% CI comparing the odds of the outcome for those above that threshold relative to those below the threshold. These analyses were stratified by (SBP $\leq$ 100 mm Hg vs SBP $>$ 100 mm Hg) and a test for interaction was used to assess evidence of effect modification between lactate and SBP. We further investigated the lactate threshold of $\geq$ 2 mmol/L in both SBP groups stratified by presumed source of infection. A $P < 0.01$ was considered statistically significant. We considered an adverse outcome rate of more than 10% (IHM or ICU 72 hours) to be clinically important in line with similar threshold adopted by recent sepsis definitions working group.¹

Reported results are based on the set including imputed data for all 12 349 patients. Results for the subgroup of patients with directly measured lactate and SBP are also presented as online supplementary tables.

RESULTS

Subjects

Between June 2010 and December 2013, the CEC Sepsis Register included 12 349 adult patients. A total of 8310

patients (67.3%) had an initial serum lactate measurement on presenting to ED. Almost all of these patients (97.6%; 8111/8310) were reviewed by a clinician for initial assessment and lactate measured within 3 hours of presentation along with usual laboratory investigations and blood cultures. Participating sites reported initial SIRS criteria (including SBP) value and lactate values at the time of sepsis recognition (online supplementary tables). While the SEPSIS KILLS pathway advocated the repeat measurements of lactate in patients with initial levels $\geq$ 4 mmol/L, this information was not specifically collected. Missing data for lactate measurements (32.7%) and SBP (7.8%) were imputed as previously described, allowing all 12 349 patients to be included in risk stratification and logistic modelling to investigate the influence of specific lactate threshold levels.

Patient characteristics are reported in table 1. The median age was 72.4 years (IQR 58.1–82.6); no sex delineation data were available. The estimated median lactate and SBP levels were 2.0 mmol/L and 121 mm Hg, respectively. In the cohort of 8310 patients in whom lactate measurements were available, the combined AE rate (IHM or ICU 72 hours) was 11.8% (983/8310) and IHM was 9.0% (751/8310). The one-third of patients (32.7%) who did not have serum lactate measured on arrival suffered significantly less AE (7.0%, 281/4039, $P < 0.002$) and IHM (6.3%, 254/4039; $P < 0.002$). IHM rate was 7.9% (977/12 349), and combined AE rate was 10.2% (1261/12 349) in overall cohort (table 2).

Relationship between AE and IHM and serum lactate level

Analysis of the cohort based on lactate groupings revealed an increase in the proportion of patients suffering AE, including IHM alone, as lactate level increased. For both

Table 1 Patient characteristics, location of service and source of infection (reported and imputed estimates shown for lactate)

Cohort	Variable	Number	Median (IQR)
Total	Age (years)	12 349	72.6 (58.1–82.6)
	Lactate (measured), mmol/L	8310 (67.3%)	1.9 (1.3–2.9)
	Lactate (imputed data), mmol/L	12 349	2.0 (1.2–3.1)
	SBP (reported), mm Hg	11 383 (92.2%)	121 (100–140)
	SBP (imputed data), mm Hg	12 349	121 (102–141)
Rural ED	Age (years)	3713	72.5 (60.1–82.1)
Metropolitan ED	Age (years)	3544	74.1 (59.1–84.2)
Tertiary ED	Age (years)	5092	70.9 (55.3–81.9)
Percentage (95% CI)			
Presumed source	Abdomen	1028	8.3 (7.9 to 8.8)
	Lung	5051	40.9 (40.1 to 41.8)
	Skin/soft tissue	933	7.6 (7.1 to 8.0)
	Urinary tract	2909	23.6 (22.8 to 24.3)
	Unknown	1252	10.1 (9.6 to 10.7)
	Other	1176	9.5 (9.0 to 10.1)

ED, emergency department; SBP, systolic blood pressure.

Table 2 Inhospital mortality (IHM) and adverse event (AE) outcome (IHM or ICU 72 hours) rates by lactate groups

Lactate group (mmol/L)	n	Age (years), median (IQR)	Lactate (mmol/L), median (IQR)	AE number (%; 95% CI)	IHM number (%; 95% CI)
0–<1	1880	69.1 (48.1–79.4)	0.6 (0.0–0.8)	78 (4.2, 3.3 to 5.2)	55 (2.9, 2.3 to 3.8)
1 to <2	4296	72.1 (57.0–82.1)	1.4 (1.2–1.7)	272 (6.3, 5.6 to 7.1)	203 (4.7, 4.1 to 5.4)
2 to <3	2745	73.1 (60.3–83.0)	2.4 (2.2–2.7)	243 (8.9, 7.8 to 10.0)	181 (6.6, 5.7 to 7.6)
3 to <4	1564	74.3 (61.9–83.5)	3.4 (3.2–3.7)	186 (11.9, 10.4 to 13.6)	146 (9.3, 8.0 to 10.9)
≥4	1864	74.1 (60.9–84.0)	5.1 (4.4–6.3)	482 (25.9, 23.9 to 27.9)	392 (21.0, 19.2 to 22.9)
Total	12349	72.6 (58.1–82.6)	2 (1.3–3.2)	10.2 (9.7 to 10.8)	7.9 (7.5 to 8.4)

AE defined as IHM or prolonged ICU length of stay (ICU 72 hours).
ICU, intensive care unit.

outcomes, the increase took the form of an exponential trend ($P<0.0001$) (table 2).

Relationship between AE and IHM and serum lactate level, stratified for hypotension

When stratified by SBP on presentation (SBP >100 mm Hg and SBP ≤100 mm Hg), the ORs of AE and IHM increased as the lactate threshold increased from 2 to 4 mmol/L (tables 3 and 4). While this study has limited power to detect effect modification between lactate and SBP, logistic regression models revealed no evidence of interaction at any threshold. After removing the interaction term from each model, both main effects for lactate and SBP were highly statistically significant ($P<0.0001$) at every lactate threshold. For AE, the estimated ORs were 2.71 (95% CI 2.05 to 3.57), 2.65 (95% CI 2.29 to 3.08), 3.10 (95% CI 2.71 to 3.53) and 3.89

(95% CI 3.36 to 4.50) for lactate thresholds of 1, 2, 3 and 4 mmol/L, respectively (all $P<0.0001$). For IHM, the estimated ORs for lactate (adjusted for SBP) were 2.93 (95% CI 2.08 to 4.13), 2.77 (95% CI 2.34 to 3.29), 3.26 (95% CI 2.80 to 3.80) and 4.01 (95% CI 3.40 to 4.73), respectively.

Lactate cut-offs in cohort stratified across predicted source in ED

The respiratory tract (40.9%), followed by urinary tract and abdominal causes were the most common presumed infection sources. A lactate cut-off of ≥2 mmol/L was associated with >10% combined AE rate (ICU 72 hours and/or IHM) for those in whom the presumed source of infection was respiratory or abdominal, with slightly lower AE rates attributed to urinary tract infection at that level (9.4%) (table 5).

Table 3 OR for AE outcome (death or ICU 72 hours) at integer lactate cut-offs in cohort split at qSOFA threshold of SBP ≤100 mm Hg

Lactate cut-off (mmol/L)	SBP >100 mm Hg			SBP ≤100 mm Hg		
	n	AE* number (%; 95% CI)	OR† (95% CI)	n	AE* number (%; 95% CI)	OR† (95% CI)
Total cohort	9391	713 (7.6, 7.1 to 8.1)	NA	2958	548 (18.5, 17.2 to 20.0)	NA
1						
<1	1564	56 (3.6, 2.8 to 4.6)	2.47 (1.78 to 3.42)	315	22 (7.0, 4.7 to 10.3)	3.34 (1.99 to 5.60)
≥1	7827	657 (8.4, 7.8 to 9.0)		2643	526 (19.9, 18.4 to 21.4)	
2						
<2	4984	237 (4.8, 4.2 to 5.4)	2.42 (2.01 to 2.91)	1192	112 (9.4, 7.9 to 11.2)	3.14 (2.44 to 4.04)
≥2	4407	476 (10.8, 9.9 to 11.8)		1766	436 (24.7, 22.7 to 26.8)	
3						
<3	7073	377 (5.3, 4.8 to 5.9)	3.01 (2.53 to 3.58)	1847	216 (11.7, 10.3 to 13.2)	3.23 (2.59 to 4.02)
≥3	2318	336 (14.5, 13.1 to 16.0)		1111	332 (29.9, 27.3 to 32.6)	
4						
<4	8208	476 (5.8, 5.3 to 6.3)	4.06 (3.34 to 4.94)	2277	303 (13.3, 12.0 to 14.8)	3.66 (2.93 to 4.57)
≥4	1183	236 (20.1, 17.8 to 22.3)		681	245 (36.0, 32.5 to 39.7)	

*AE died or ICU length of stay (ICU 72 hours) with no overlap.

†OR and 95% CI calculated at each cut-point conducted on imputed dataset of 12349 patients.

AE, adverse event; ICU, intensive care unit; NA, not applicable; qSOFA, quick Sequential Organ Failure Assessment; SBP, systolic blood pressure.

Table 4 OR for IHM at integer lactate cut-offs in cohort split at qSOFA threshold of SBP >100 mm Hg

Lactate cut-off (mmol/L)	SBP >100 mm Hg			SBP ≤100 mm Hg		
	n	IHM number (%; 95% CI)	OR* (95% CI)	n	IHM number (%; 95% CI)	OR* (95% CI)
Total cohort	9391	541 (5.8, 5.3 to 6.3)	NA	2958	436 (14.7, 13.5 to 16.1)	NA
1						
<1	1564	38 (2.4, 1.8 to 3.3)	2.76 (1.81 to 4.21)	315	17 (5.4, 3.4 to 8.5)	3.37 (1.82 to 6.25)
≥1	7827	503 (6.4, 5.9 to 7.0)		2643	419 (15.9, 14.5 to 17.3)	
2						
<2	4984	170 (3.4, 2.9 to 4.0)	2.61 (2.10 to 3.24)	1192	88 (7.4, 6.0 to 9.0)	3.08 (2.32 to 4.09)
≥2	4407	371 (8.4, 7.6 to 9.3)		1766	348 (19.7, 17.9 to 21.6)	
3						
<3	7073	273 (3.9, 3.4 to 4.3)	3.27 (2.67 to 4.01)	1847	166 (9.0, 7.8 to 10.4)	3.25 (2.56 to 4.14)
≥3	2318	268 (11.6, 10.3 to 12.9)		1111	270 (24.3, 21.9 to 26.9)	
4						
<4	8208	353 (4.3, 3.9 to 4.8)	4.21 (3.35 to 5.28)	2277	232 (10.2, 9.0 to 11.5)	3.77 (2.96 to 4.79)
≥4	1183	188 (15.9, 13.9 to 18.1)		681	204 (30.0, 26.6 to 33.5)	

*OR and 95% CI calculated at each cut-point conducted on imputed dataset of 12349 patients.

IHM, in hospital mortality; NA, not applicable; qSOFA, quick Sequential Organ Failure Assessment; SBP, systolic blood pressure.

DISCUSSION

In this retrospective cohort analysis of a statewide quality improvement initiative in a representative statewide sample of public hospitals, we found a significantly increased risk for a combined adverse outcome (ICU stay of at least 72 hours or death in hospital) with increasing lactate threshold values. More than 1 in 10 who had an initial serum lactate of ≥2 mmol/L experienced a severe AE, irrespective of hypotension (SBP >100 mm Hg) and for almost all sources. Our dataset was derived from a quality audit tool with results applicable to the specific sepsis screening algorithm employed. Our findings on adverse outcome and sepsis risk therefore need to be demonstrated in other clinical settings, especially in those where different sepsis screening algorithms are used.

Approximately one-third of patients (32.7%) identified as suspected sepsis in the register did not undergo lactate measurement in ED. Our analysis for AEs in this group indicated less AE and mortality risk than for those in who serum lactate was measured. While a complex multiple imputation using limited available variables was conducted to account for missing data, the lack of true lactate measurements in this group may have impacted our overall study results. It is difficult to predict the direction of such an impact, but our finding of incrementally increased risk for in-hospital adverse outcomes with increasing lactate levels is consistent with other reports.¹⁶ Our mortality rates of 21% in patients with suspected sepsis with a lactate level ≥4 mmol/L are lower than previously reported from the USA⁹ but are in keeping with past findings for patients treated in Australian ICUs for severe sepsis and septic shock.¹⁷ While previous studies have used SBP <90 mm Hg to define hypotension, we selected a cut-off of SBP ≤100 mm Hg, in line with

recommendations under the recently revised sepsis definitions for predicting sepsis, including qSOFA, as these are likely to be widely adopted for identifying patients at risk for adverse outcomes.¹ Our mortality rates of 8.4% in the absence of hypotension (SBP >100 mm Hg) and 19.7% with SBP ≤100 mm Hg and lactate ≥2 mmol/L are in keeping with previous reports.^{8, 18} As part of the SEPSIS KILLS pathway implementation, sites were advised to voluntarily report on the SIRS variables and investigations results data (lactate level) at the time of initiation of the sepsis management bundle. While most patients had these done within the first few hours of arrival in ED, it is difficult to decipher the exact timing of these data endpoints in each case. Thus, strong conclusions regarding timing of SIRS and lactate level thresholds cannot be derived or promulgated from our analysis.

AE rates (10.8% and 24.7%) and IHM (8.4% and 19.7%) in patients with initial lactate levels of ≥2 mmol/L and SBP >100 mm Hg and ≤100 mm Hg, respectively, are therefore consistent with previous findings, and suggest that initial serum lactate ≥2 mmol/L is more appropriate than ≥4 mmol/L for entry into sepsis management pathways and for identification of an increased risk of death.¹¹ We noted a near doubling of AE and IHM rates in patients with initial lactate levels ≥4 mmol/L when compared with those with less than 4 mmol/L, in keeping with findings in a similar ED cohort.¹⁸

As the health burden of sepsis becomes increasingly apparent,¹⁹ global initiatives such as the SCC³ have led to the increasing use of screening algorithms in the ED. These algorithms result in the implementation of management bundles which have been shown to improve outcomes in sepsis.²⁰ One of the key interventions in these bundles is the escalation of clinical supervision

Table 5 IHM and adverse outcomes (IHM or ICU 72 hours) in cohorts based on predicted source and lactate cut-off ≥ 2 mmol/L

Presumed source	Lactate cut-off (mmol/L)	Adverse event*				IHM*		
		Number/total	Per cent (95% CI)	OR (95% CI)	Number/total	Per cent (95% CI)	OR (95% CI)	
Lung	< 2	183/2682	6.8 (5.9 to 7.8)	2.92 (2.37 to 3.60)	136/2682	5.1 (4.3 to 6.0)	3.11 (2.46 to 3.92)	
	≥ 2	418/2369	17.6 (16.2 to 19.2)		344/2369	14.5 (13.2 to 16.0)		
Urinary tract	< 2	49/1453	3.4 (2.6 to 4.4)	3.01 (2.09 to 4.35)	39/1453	2.7 (2.0 to 3.6)	3.00 (2.00 to 4.45)	
	≥ 2	137/1456	9.4 (8.0 to 11.0)		109/1456	7.5 (6.3 to 9.0)		
Abdomen	< 2	22/437	5.0 (3.3 to 7.5)	4.48 (2.72 to 7.38)	11/437	2.5 (1.4 to 4.5)	6.92 (3.53 to 13.57)	
	≥ 2	111/591	18.8 (15.8 to 22.1)		88/591	14.9 (12.3 to 18.0)		
Skin/soft tissue	< 2	26/450	5.8 (4.0 to 8.3)	2.06 (1.22 to 3.49)	24/450	5.3 (3.6 to 7.8)	1.60 (0.91 to 2.81)	
	≥ 2	54/483	11.2 (8.7 to 14.3)		41/483	8.5 (6.3 to 11.3)		
Unknown	< 2	39/536	7.3 (5.4 to 9.8)	2.46 (1.62 to 3.74)	27/536	5.0 (3.5 to 7.2)	2.52 (1.52 to 4.18)	
	≥ 2	117/716	16.3 (13.8 to 19.2)		83/716	11.6 (9.5 to 14.1)		
Other†	< 2	31/617	5.0 (3.6 to 7.0)	2.88 (1.82 to 4.56)	22/617	3.6 (2.4 to 5.3)	2.89 (1.67 to 5.01)	
	≥ 2	74/559	13.2 (10.7 to 16.3)		53/559	9.5 (7.3 to 12.2)		
Total	< 2	350/6176	5.7 (5.1 to 6.3)	2.88 (2.49 to 3.34)	258/6176	4.2 (3.7 to 4.7)	3.03 (2.56 to 3.58)	
	≥ 2	911/6173	14.8 (13.9 to 15.7)		719/6173	11.7 (10.9 to 12.5)		

*OR and 95% CI calculated at lactate cut-off of 2 mmol/L conducted on imputed dataset of 12 349 patients.

†Other includes orthopaedic, central nervous system, vascular device infections, ICU, intensive care unit; IHM, in-hospital mortality.

through referral of care to senior clinicians and ICUs. Our composite AE endpoint is designed to address this directly.

We have previously reported on the performance of various international sepsis screening algorithms using a range of lactate thresholds.¹¹ Recent statements from the Surviving Sepsis Committee have suggested the need for closer observation of patients who meet the new sepsis criteria with qSOFA ≥ 2 .²¹ The recent shift in definitions of sepsis based on SOFA scores, which requires calculations based on investigations' results is unlikely to uniformly occur in ED patients presenting with suspected infection. Our findings indicate that lactate ≥ 2 mmol/L should be incorporated as a risk predictor in ED patients with suspected sepsis.

Author affiliations

¹NHMRC Centre for Research Excellence in Critical Excellence, Westmead Millennium Institute for Medical Research, Westmead, New South Wales, Australia

²Emergency Department, Westmead Hospital, Westmead, New South Wales, Australia

³Division of Critical Care and Trauma, The George Institute for Global Health, Sydney, New South Wales, Australia

⁴NHMRC Clinical Trial Centre, University of Sydney, Sydney, New South Wales, Australia

⁵Research and Education Network, Western Sydney Local Health District, Sydney, New South Wales, Australia

⁶Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia

⁷Adult Patient Safety Program, Clinical Excellence Commission, Sydney, New South Wales, Australia

⁸Systems Improvement, Clinical Excellence Commission, Sydney South, New South Wales, Australia

⁹Infectious Diseases and Intensive care, Westmead Hospital, Westmead, New South Wales, Australia

Acknowledgements The authors would like to thank the medical and nursing staff across the NSW Health service who were involved in the implementation of SEPSIS KILLS programme and data reporting resulting in the creation of the sepsis register.

Contributors ALS was responsible for the data collation, and data analysis for the study was conducted by KB and PM. MG, MF and HL represented CEC and sepsis register development group and responsible for the provision and release of data. ALS and KT prepared the initial draft for the manuscript and JI supervised, guided the project and manuscript development through to final editing process. All authors were intricately involved in the development, revisions and final approval of the manuscript.

Competing interests None declared.

Ethics approval NSW Health Human Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement The sepsis register is maintained by the CEC for NSW Health was developed as a public health and disease register under s98 of the Public Health Act 2011. Application for data release may be made through the Right of information Officer, NSW Ministry of Health under the provisions of the Government Information (Public Access) Act 2009.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which

permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

1. Singer M, Deutschman CS, Seymour CW, *et al.* The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016;315:801–10.
2. Liu V, Escobar GJ, Greene JD, *et al.* Hospital deaths in patients with sepsis from 2 independent cohorts. *JAMA* 2014;312:90–2.
3. Dellinger RP, Levy MM, Rhodes A, *et al.* Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. *Intensive Care Med* 2013;39:165–228.
4. Shankar-Hari M, Phillips GS, Levy ML, *et al.* Developing a new definition and assessing new clinical criteria for septic shock: for the third International Consensus Definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016;315:775–87.
5. Rhodes A, Evans LE, Alhazzani W, *et al.* Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. *Intensive Care Med* 2017;43:304–77.
6. Jones AE, Puskarch MA. The surviving sepsis campaign guidelines 2012: update for emergency physicians. *Ann Emerg Med* 2014;63.
7. Gotmaker R, Peake SL, Forbes A, *et al.* Mortality is greater in septic patients with hyperlactatemia than with refractory hypotension. *Shock* 2017;48:294–300.
8. Puskarch MA, Illich BM, Jones AE. Prognosis of emergency department patients with suspected infection and intermediate lactate levels: a systematic review. *J Crit Care* 2014;29:334–9.
9. Casserly B, Phillips GS, Schorr C, *et al.* Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. *Crit Care Med* 2015;43:567–73.
10. Garcia-Alvarez M, Marik P, Bellomo R. Sepsis-associated hyperlactatemia. *Crit Care* 2014;18:503.
11. Shetty AL, Brown T, Booth T, *et al.* Systemic inflammatory response syndrome-based severe sepsis screening algorithms in emergency department patients with suspected sepsis. *Emerg Med Australas* 2016;28:287–94.
12. Burrell AR, McLaws ML, Fullick M, *et al.* SEPSIS KILLS: early intervention saves lives. *Med J Aust* 2016;204:73.
13. Sterne JA, White IR, Carlin JB, *et al.* Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *BMJ* 2009;338:b2393.
14. Moons KG, Donders RA, Stijnen T, *et al.* Using the outcome for imputation of missing predictor values was preferred. *J Clin Epidemiol* 2006;59:1092–101.
15. *IBM SPSS statistics for windows [program]*. Armonk, NY, 2015. Version 23.0 version.
16. Nichol AD, Egi M, Pettila V, *et al.* Relative hyperlactatemia and hospital mortality in critically ill patients: a retrospective multi-centre study. *Crit Care* 2010;14:R25.
17. Kaukonen KM, Bailey M, Suzuki S, *et al.* Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. *JAMA* 2014;311:1308–16.
18. Shapiro NI, Howell MD, Talmor D, *et al.* Serum lactate as a predictor of mortality in emergency department patients with infection. *Ann Emerg Med* 2005;45:524–8.
19. Fleischmann C, Scherag A, Adhikari NK, *et al.* Global burden of sepsis: a systematic review. *Critical Care* 2015;19(Suppl 1):P21.
20. Levy MM, Pronovost PJ, Dellinger RP, *et al.* Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. *Crit Care Med* 2004;32:S595–S597.
21. Antonelli Massiomo DD, Todd D, Ruth K, *et al.* Surviving sepsis campaign responds to Sepsis-3. 2016 <http://www.survivingsepsis.org/guidelines/Pages/default.aspx>